Interplay of Anti-Viral Vaccines with Biologic Agents and Immunomodulators in Individuals with Autoimmune and Autoinflammatory Diseases

References

• Ali A, Kamjani MH, Kessleman MM. 2020. The role of tocilizumab in cytokine storm and improving outcomes in COVID-19. Recent Pat Antiinfect Drug Discov. 15(2):104–12.
   PubMedGoogle Scholar
• Alten R, Bingham CO 3rd, Cohen SB, Curtis JR, Kelly S, Wong D, Genovese MC. 2016. Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept. BMC Musculoskelet Disord. 17:231. doi:10.1186/s12891-016-1082-z.
   PubMed Web of Science ®Google Scholar
• American College of Rheumatology COVID-19 Vaccine Clinical Guidance Summary for Patients with Rheumatic and Musculoskeletal Diseases Developed by the ACR COVID-19 Vaccine Clinical Guidance Task Force. 2021. Updated Feb 8. [accessed 2021 Mar 5]. https://www.rheumatology.org/Portals/0/Files/COVID-19-Vaccine-Clinical-Guidance-Rheumatic-Diseases-Summary.pdf.
   Google Scholar
• Amsterdam D, Ostrov BE. 2018. The impact of the microbiome on immunosenescence. Immunol Invest. 47(8):801–11.
   PubMed Web of Science ®Google Scholar
• Baddley JW, Cantini F, Goletti D, Gómez-Reino JJ, Mylonakis E, San-Juan R, Fernández-Ruiz M, Torre-Cisneros J. 2018. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents). Clin Microbiol Infect. 24(Suppl 2):S10–S20.
   PubMed Web of Science ®Google Scholar
• Baumrin E, Van Voorhees A, Garg A, Feldman SR, Merola JF. 2019. A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 81(1):102–10.
   PubMed Web of Science ®Google Scholar
• Black S, Nicolay U, Vesikari T, Knuf M, Del Giudice G, Della Cioppa G, Tsai T, Clemens R, Rappuoli R. 2012. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J. 30(12):1081–85.
   Web of Science ®Google Scholar
• Brogan PA, Hofer M, Kuemmerle-Deschner JB, Koné-Paut I, Roesler J, Kallinich T, Horneff G, Calvo Penadés I, Sevilla-Perez B, Goffin L, et al. 2019. Rapid and sustained long-term efficacy and safety of canakinumab in patients with cryopyrin-associated periodic syndrome ages five years and younger. Arthritis Rheumatol. 71(11):1955–63. doi:10.1002/art.41004
   PubMed Web of Science ®Google Scholar
• Cagigi A, Cotugno N, Rinaldi S, Santilli V, Rossi P, Palma P. 2016. Downfall of the current antibody correlates of influenza vaccine response in yearly vaccinated subjects: toward qualitative rather than quantitative assays. Pediatr Allergy Immunol. 27(1):22–27.
   PubMed Web of Science ®Google Scholar
• Calabrese LH, Abud-Mendoza C, Lindsey SM, Lee SH, Tatulych S, Takiya L, Iikuni N, Soma K, Luo Z, Fleischmann R. 2020. Live zoster vaccine in patients with rheumatoid arthritis treated with tofacitinib with or without methotrexate, or adalimumab with methotrexate: a post Hoc analysis of data from a Phase IIIb/IV randomized study. Arthritis Care Res (Hoboken). 72(3):353–59.
   PubMed Web of Science ®Google Scholar
• Camacho-Lovillo MS, Bulnes-Ramos A, Goycochea-Valdivia W, Fernandez-Silveria L, Nunez-Cuadros E, Neth O, Perez-Romero P. 2017. Immunogenicity and safety of influenza vaccination in patients with juvenile idiopathic arthritis on biological therapy using the microneutralization assay. Ped Rheum. 15(1):62–72.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. 2020b. Estimated influenza illnesses, medical visits, hospitalizations and deaths in the United States – 2018–2019 influenza season. [accessed 2021 Jan 8]. https://www.cdc.gov/flu/about/burden/2018-2019.html#:~:text=CDC%20estimates%20that%20influenza%20was,2012%E2%80%932013%20influenza%20season1.
   Google Scholar
• Centers for Disease Control and Prevention. 2020c. Varicella. [accessed 2020 Dec 31]. https://www.cdc.gov/vaccines/pubs/pinkbook/varicella.html#:~:text=The%20fatality%20rate%20for%20varicella,in%20immunocompetent%20children%20and%20adults
   Google Scholar
• Centers for Disease Control and Prevention. Advisory Committee on Immunization practices. 2020a. ACIP vaccine recommendations and guidelines. US Department of Health and Human Services. [accessed 2021 Mar 4]. https://www.cdc.gov/vaccines/hcp/acip-recs
   Google Scholar
• Chatham WW, Wallace DJ, Stohl W, Latinis KM, Manzi S, McCune WJ, Tegzová D, McKay JD, Avila-Armengol HE, Utset TO, et al. 2012. Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial. J Rheumatol. 39(8):1632–40.
   PubMed Web of Science ®Google Scholar
• Chen X, Liu S, Goraya MU, Maarouf M, Huang S, Chen JL. 2018. Host immune response to influenza A virus infection. Front Immunol. 9:320.
   PubMed Web of Science ®Google Scholar
• Chioato A, Noseda E, Felix SD, Stevens M, Del Giudice G, Fitoussi S, Kleinschmidt A. 2010. Influenza and meningococcal vaccinations are effective in healthy subjects treated with the interleukin-1-blocking antibody canakinumab: results of an open-label, parallel group, randomized, single-center study. Clin Vaccine Immunol. 17(12):1952–57.
   PubMedGoogle Scholar
• Ciabattini A, Nardini C, Santoro F, Garagnani P, Franceschi C, Medaglini D. 2018. Vaccination in the elderly: the challenge of immune system changes with aging. Sem Immunol. 40:83–94.
   PubMed Web of Science ®Google Scholar
• Davis JS, Ferreira D, Paige E, Gedye C, Boyle M. 2020. Infectious complications of biological and small molecule targeted immunomodulatory therapies. Clin Microbiol Rev. 33(3):1–117 e00035–19.
   Web of Science ®Google Scholar
• Franca IL, Ribeiro AC, Aikawa NE, Saad CG, Moraes JC, Goldstein-Schainberg C, Laurindo IM, Precioso AR, Ishida MA, Sartori AM, et al. 2012. TNF blockers show distinct patterns of immune response to the pandemic influenza A H1N1 vaccine in inflammatory arthritis patients. Rheumatology (Oxford). 51(11):2091–98. doi:10.1093/rheumatology/kes202
   PubMed Web of Science ®Google Scholar
• Friedman MA, Winthrop KL. 2017. Vaccines and disease modifying antirheumatic drugs. Practical implications for the rheumatologists. Rheum Dis Clin N Am. 43(2017):1–13.
   PubMedGoogle Scholar
• Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, Van Assen S, Bijl M, Breedveld FC, D’Amelio R, Dougados M, Kapetanovic MC, et al. 2020. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 79(1):39–52.
   Web of Science ®Google Scholar
• Hauptman M, Vasic J, Krase J. 2021. COVID-19 vaccine and biologics: an impending dilemma. J Drugs Dermatol. 20(1):114–15.
   Web of Science ®Google Scholar
• Hruz P, Juillerat P, Kullak-Ublick GA, Schoepfer AM, Mantzaris GJ, Rogler G; on behalf of Swiss IBDnet, of the Swiss Society of Gastroenterology. 2020. Management of the elderly inflammatory bowel disease patient. Digestion 101(Suppl 1):105–19. doi:10.1159/000503099
   PubMed Web of Science ®Google Scholar
• Iannacone M, Sitia G, Ruggeri ZM, Guidotti LG. 2007. HBV pathogenesis in animal models: recent advances on the role of platelets. J Hepatol. 46(4):719–26.
   PubMed Web of Science ®Google Scholar
• Jacobson DL, Bousvaros A, Ashworth L, Carey R, Shrier LA, Burchett SK, Renna H, Lu Y. 2013. Immunogenicity and tolerability to human papillomavirus-like particle vaccine in girls and young women with inflammatory bowel disease. Inflamm Bowel Dis. 19(7):1441–49.
   PubMed Web of Science ®Google Scholar
• Jaeger VK, Hoffman HM, van der Poll T, Tilson H, Seibert J, Speziale A, Junge G, Franke K, Vritzali E, Hawkins PN, et al. 2017. Safety of vaccinations in patients with cryopyrin-associated periodic syndromes: a prospective registry based study. Rheumatology (Oxford). 56(9):1484–91. doi:10.1093/rheumatology/kex185
   PubMed Web of Science ®Google Scholar
• Jamilloux Y, Henry T, Belot A, Viel S, Fauter M, El Jammal T, Walzer T, Francois B, Seve P. 2020. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmun Rev. 19(7):102567.
   PubMed Web of Science ®Google Scholar
• Jiang HY, Wang SY, Deng M, Li YC, Ling ZX, Shao L, Ruan B. 2017. Immune response to hepatitis B vaccination among people with inflammatory bowel diseases: a systematic review and meta-analysis. Vaccine 35(20):2633–41.
   PubMed Web of Science ®Google Scholar
• Kapetanovic MC, Kristensen LE, Saxne T, Aktas T, Mörner A, Geborek P. 2014. Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis. Arthritis Res Ther. 16(1):R2. doi:10.1186/ar4427.
   PubMed Web of Science ®Google Scholar
• Kennedy DA, Read AF. 2018. Why the evolution of vaccine resistance is less of a concern than the evolution of drug resistance. Proc Nat’l Acad Sci USA. 115(51):12878–86.
   PubMed Web of Science ®Google Scholar
• Kennedy DA, Read AF. 2020. Monitor for COVID-19 vaccine resistance evolution during clinical trials. PLoS Biol. 18(11):e3001000.
   PubMed Web of Science ®Google Scholar
• Kivitz AJ, Schechtman J, Texter M, Fichtner A, De Longueville M, Chartash EK. 2014. Vaccine responses in patients with rheumatoid arthritis treated with certolizumab pegol: results from a single-blind randomized phase IV trial. J Rheumatol. 41(4):648–57.
   PubMed Web of Science ®Google Scholar
• Kobie JJ, Zheng B, Bryk P, Barnes M, Ritchlin CT, Tabechian DA, Anandarajah AP, Looney RJ, Thiele RG, Anolik JH, et al. 2011. Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor. Arthritis Res Ther. 13(6):R209. doi:10.1186/ar3542
   PubMed Web of Science ®Google Scholar
• Krammer F, Weir JP, Engelhardt O, Katz JM, Cox RJ. 2020. Meeting report and review: immunological assays and correlates of protection for next-generation influenza vaccines. Influenza Other Respir Viruses. 14(2):237–43.
   PubMed Web of Science ®Google Scholar
• Lhomme E, Hejblum BP, Lacabaratz C, Wiedemann A, Lelièvre JD, Levy Y, Thiébaut R, Richert L. 2020. Analyzing cellular immunogenicity in vaccine clinical trials: a new statistical method including non-specific responses for accurate estimation of vaccine effect. J Immunol Methods. 477:112711.
   PubMed Web of Science ®Google Scholar
• Lorenzetti R, Janowska I, Smulski CR, Frede N, Henneberger N, Walter L, Schleyer MT, Huppe JM, Staniek J, Salzer U, et al. 2019. Abatacept modulates CD80 and CD86 expression and memory formation in human B cells. J Autoimmun. 101:145–52. doi:10.1016/j.jaut.2019.04.016. Epub 2019 May 1.
   Web of Science ®Google Scholar
• Manser CN, Maillard MH, Rogler G, Schreiner P, Rieder F, Buhler S. 2020. Vaccination in patients with inflammatory bowel disease. Digestion. 101(suppl 1):58–68.
   PubMed Web of Science ®Google Scholar
• Marin AC, Gisbert JP, Chaparro M. 2015. Immunogenicity and mechanisms impairing the response to vaccines in inflammatory bowel disease. World J Gastroenterol. 21(40):11273–81. doi:10.3748/wjg.v21.i40.11273.
   PubMed Web of Science ®Google Scholar
• Marren AS. 2017. Tofacitinib is not a biologic. Ann Gastroenterol. 30(1):134.
   PubMed Web of Science ®Google Scholar
• Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L, Rodewald LE, Douglas JM, Janssen RS, Ward JW. 2006. Centers for disease control and prevention. A comprehensive immunization strategy to eliminate transmission of hepatitis b virus infection in the United States recommendations of the advisory committee on immunization practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep. 55:1–33.
   PubMedGoogle Scholar
• Mazzola G, Macaluso FS, Adamoli L, Renna S, Cascio A, Orlando A. 2017. Diagnosis and vaccine strategies to prevent infections in patients with inflammatory bowel disease. J Infection. 74:433–41.
   PubMed Web of Science ®Google Scholar
• Melmed GY. 2012. Vaccinations while on thiopurines. Some protection is better than none. Amer J Gastroenterol. 107(1):141–42.
   PubMed Web of Science ®Google Scholar
• Meyer PA, Seward JF, Jumaan AO, Wharton M. 2000. Varicella mortality. Trends before vaccine licensure in the United States 1970–1994. J Infect Dis. 182(2):383–90.
   PubMed Web of Science ®Google Scholar
• Milanetti F, Germano V, Nisini R, Donatelli I, Di Martino A, Facchini M, Ferlito C, Cappella A, Crialesi D, Caporuscio S, et al. 2014. Safety and immunogenicity of co-administered MF59-adjuvanted 2009 pandemic and plain 2009-10 seasonal influenza vaccines in rheumatoid arthritis patients on biologicals. Clin Exp Immunol. 177(1):287–94. doi:10.1111/cei.1229
   PubMed Web of Science ®Google Scholar
• Mok CC, Ho LY, To CH. 2018. Long-term immunogenicity of a quadrivalent human papillomavirus vaccine in systemic lupus erythematosus. Vaccine. 36(23):3301–07.
   PubMed Web of Science ®Google Scholar
• Munoz-Wolf N, Lavelle EC. 2018. A guide to IL-1 family cytokines in adjuvanticity. Febs J. 285(13):2377–401.
   PubMed Web of Science ®Google Scholar
• Nagel MA, Gilden DH. 2007. The protean neurologic manifestations of varicella-zoster virus infection. Cleveland Clin J Med. 74(7):489–99passim.
   PubMed Web of Science ®Google Scholar
• Nard FD, Todoerti M, Grosso V, Monti S, Breda S, Rossi S, Montecucco C, Caporali R. 2015. Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: extending perspective from old to newer drugs. World J Hepatol. 7(3):344–61.
   PubMed Web of Science ®Google Scholar
• Ogimi C, Tanaka R, Saitoh A, Oh-Ishi T. 2011. Immunogenicity of influenza vaccine in children with pediatric rheumatic diseases receiving immunosuppressive agents. Pediatr Infect Dis J. 30(3):208–11.
   PubMed Web of Science ®Google Scholar
• Oishi S, Wendling D, Sibilia J, Job-Deslandre C, Guillevin L, Benichou J, Flipo RM, Duquenne C, Guillemin F, Saraux A. 2018. Treatment of active rheumatoid arthritis: comparison of patients younger vs older than 75 years (CORPUS cohort). Hum Vaccin Immunother. 14(11):2612–17.
   PubMed Web of Science ®Google Scholar
• Ostrov BE. 2015. Immunotherapeutic biologic agents in treating autoimmune and autoinflammatory diseases. Immunological Inv. 44(8):777–802.
   PubMed Web of Science ®Google Scholar
• Papp KA, Haraoui B, Kumar D, Marshall JK, Bissonnette R, Bitton A, Bressler B, Gooderham M, Ho V, Jamal S, et al. 2019. Vaccination guidelines for patients with immune-mediated disorders on immunosuppressive therapies. J Cutan Med Surg. 23(1):50–74. doi:10.1177/1203475418811335
   PubMed Web of Science ®Google Scholar
• Park JK, Lee YJ, Shin K, Ha YJ, Lee EY, Song YW, Choi Y, Winthrop KL, Lee EB. 2018. Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomized clinical trial. Ann Rheum Dis. 77(6):898–904.
   PubMed Web of Science ®Google Scholar
• Parrino J, McNeil SA, Lawrence SJ, Kimby E, Pagnoni MF, Stek JE, Zhao Y, Chan IS, Kaplan SS. 2017. Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with hematologic malignancies receiving treatment with anti-CD20 monoclonal antibodies. Vaccine 35(14):1764–69.
   PubMed Web of Science ®Google Scholar
• Plotkin SA. 2010. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 17(7):1055–65.
   PubMed Web of Science ®Google Scholar
• Pombo-Suarez M, Gomez-Reino JJ. 2019. Abatacept for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 15(4):319–26.
   PubMed Web of Science ®Google Scholar
• Pratt PK Jr, David N, Weber HC, Little FF, Kourkoumpetis T, Patts GJ, Weinberg J, Farraye FA. 2018. Antibody response to hepatitis B virus vaccine is impaired in patients with inflammatory bowel disease on infliximab therapy. Inflamm Bowel Dis. 24(2):380–86.
   PubMed Web of Science ®Google Scholar
• Raimondo MG, Biggioggero M, Crotti C, Becciolini A, Favalli EG. 2017. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. Drug Des Devel Ther. 11:1593–603.
   PubMed Web of Science ®Google Scholar
• Ramiro S, Sepriano A, Chatzidionysiou K, Nam JL, Smolen JS, van der Heijde D, Dougados M, van Vollenhoven R, Bijlsma JW, Burmester GR, et al. 2017. Safety of synthetic and biological DMARDS: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 76(6):1101–36.
   PubMed Web of Science ®Google Scholar
• Ribeiro AC, Laurindo IM, Guedes LK, Saad CG, Moraes JC, Silva CA, Bonfa E. 2013. Abatacept and reduced immune response to pandemic 2009 influenza A/H1Na vaccination in patients with rheumatoid arthritis. Arthritis Care Res. 65(3):476–80.
   Web of Science ®Google Scholar
• Richi P, Alonso O, Martin MD, Martín MD, González-Hombrado L, Navío T, Salido M, Llorente J, Andreu-Vázquez C, García-Fernández C, et al. 2020. Evaluation of the immune response to hepatitis B vaccine in patients on biological therapy: results of the RIER cohort study. Clin Rheumatol. 39(9):2751–56.
   PubMed Web of Science ®Google Scholar
• Richi P, Martín MD, Navío MT, González-Hombrado L, Salido M, Llorente J, Thuissard-Vasallo I, Alcocer P, Saa-Requejo CM, Jiménez-Diaz A, et al. 2019. Antibody responses to influenza vaccine in patients on biological therapy: results of RIER cohort study. Med Clin (Barc). 153(10):380–86. doi:10.1016/j.medcli.2019.02.003.
   PubMed Web of Science ®Google Scholar
• Rizzi M, Lorenzetti R, Fischer K, Staniek J, Janowska I, Troilo A, Strohmeier V, Erlacher M, Kunze M, Bannert B, et al. 2017. Impact of tofacitinib treatment on human B-cells in vitro and in vivo. J Autoimmun. 77:55–66.
   PubMed Web of Science ®Google Scholar
• Rollet-Cohen V, Mirete J, Dingulu G, Hofer F, Hofer M, Woerner A, Dommergues MA, Hentgen V. 2021. Suboptimal vaccination coverage of recommended vaccines among French children with recurrent autoinflammatory fever syndromes: a study from the Juvenile inflammatory rheumatism cohort. Clin Rheumatol. doi:10.1007/s10067-020-05553-y
   PubMed Web of Science ®Google Scholar
• Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, Bousvaros A, Dhanireddy S, Sung L, Keyserling H, et al.; Infectious Diseases Society of America. 2014. 2013 IDSA clinical practice guidelines for vaccination of the immunocompromised host. Clin Infect Dis. 58(3):309–18.
   Google Scholar
• Shinoki T, Hara R, Kaneko U, Miyamae T, Imagawa T, Mori M, Yokota S. 2012. Safety and response to influenza vaccine in patients with systemic-onset juvenile idiopathic arthritis receiving tocilizumab. Mod Rheumatol. 22(6):871–76.
   PubMed Web of Science ®Google Scholar
• Shirota Y, Yarboro C, Fischer R, Pham TH, Lipsky P, Illei GG. 2013. Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus. Ann Rheum Dis. 72(1):118–28.
   PubMed Web of Science ®Google Scholar
• Solay AH, Eser F. 2019. High dose hepatitis B vaccine is not effective in patients using immunomodulatory drugs: a pilot study. Hum Vaccin Immunother. 15(5):1177–82.
   PubMed Web of Science ®Google Scholar
• Stanley M. 2006. Immune responses to human papillomavirus. Vaccine. 24(Suppl 1):S16–22.
   PubMed Web of Science ®Google Scholar
• Subesinghe S, Bechman K, Rutherford AI, Goldblatt D, Galloway JB. 2018. A systematic review and metaanalysis of antirheumatic drugs and vaccine immunogenicity in rheumatoid arthritis. J Rheumatol. 45(6):733–44.
   PubMed Web of Science ®Google Scholar
• Van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, Emery P, Geborek P, Ioannidis JP, Jayne DR, et al. 2011. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 70(3):414–22.
   PubMed Web of Science ®Google Scholar
• Verschoor CP, Andrew MK, Loeb M, Pawelec G, Haynes L, Kuchel GA, McElhaney JE. 2021. Antibody and cell-mediated immune responses are correlates of protection against influenza infection in vaccinated older adults. Vaccines (Basel). 9(1):25.
   PubMed Web of Science ®Google Scholar
• Verschoor CP, Singh P, Russell ML, Bowdish DME, Brewer A, Cyr L, Ward BJ, Loeb M. 2015. Microneutralization assay titres correlate with protection against seasonal influenza H1N1 and H3N2 in children. PLoS One. 10(6):7–13.
   Web of Science ®Google Scholar
• Walsh EE, Frenck R, Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R, et al. 2020. Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates. N Engl J Med. 383(25):2439–50.
   PubMed Web of Science ®Google Scholar
• Wang BX, Fish EN. 2019. Global virus outbreaks: interferons as 1st responders. Semin Immunol. 43:101300.
   PubMed Web of Science ®Google Scholar
• Westra J, van Assen S, Wilting KR, Land J, Horst G, de Haan A, Bijl M. 2014. Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients. Clin Exp Immunol. 78(1):40–47.
   Google Scholar
• Whitaker JA. 2020. Immune strategies to span the spectrum of immunocompromised adults. Mayo Clin Proc. 95(7):1530–48.
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Mariette X, Silva JT, Benamu E, Calabrese LH, Dumusc A, Smolen JS, Aguado JM, Fernadez-Ruiz M. 2018. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect. 24(Suppl 2):S21–S40.
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Silverfield J, Racewicz A, Neal J, Lee EB, Hrycaj P, Gomez-Reino J, Soma K, Mebus C, Wilkinson B, et al. 2016. The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. Ann Rheum Dis. 75:687–95.
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Wouters AG, Choy EH, Soma K, Hodge JA, Nduaka CI, Biswas P, Needle E, Passador S, Mojcik CF, et al. 2017. The safety and immunogenicity of live zoster vaccination in patients with rheumatoid arthritis before starting tofacitinib: a randomized phase II trial. Arthritis Rheumatol. 69:1969–7778.
   PubMed Web of Science ®Google Scholar
• Wong PKK, Hanrahan P. 2018. Management of vaccination in rheumatic disease. Best Prac Res Clin Rheum. 32(2018):720–34.
   PubMedGoogle Scholar
• Yun H, Xie F, Delzell E, Chen L, Levitan EB, Lewis JD, Saag KG, Beukelman T, Winthrop K, Baddley JW, et al. 2015. Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy. Arthritis Care Res. 67(5):731–36.
   PubMed Web of Science ®Google Scholar
• Zimmerman P, Curtis N. 2019. Factors that influence the immune response to vaccination. Clin Microbiol Rev. 32(2):1–50; e0084–18.
   Web of Science ®Google Scholar